Sirio Pharma Co., Ltd. (SHE:300791)
China · Delayed Price · Currency is CNY 18.10
+0.97 (5.66%)
May 29, 2026, 3:04 PM CST
Sirio Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Net Income | 117.8 | 136.53 | 325.06 | 281.04 | 212.29 | 231.83 |
Depreciation & Amortization | 233.75 | 233.75 | 239.27 | 256.96 | 131.74 | 104.06 |
Other Amortization | 96.28 | 96.28 | 49.17 | 6.08 | 4.64 | 2.54 |
Loss (Gain) From Sale of Assets | -2.43 | -2.43 | -0.24 | -0.03 | 5.34 | -0.16 |
Asset Writedown & Restructuring Costs | 137.18 | 137.18 | 4.41 | 0.95 | 0.17 | -0.56 |
Loss (Gain) From Sale of Investments | 0.71 | 0.71 | 28.96 | 52.06 | -21.76 | -24.14 |
Stock-Based Compensation | 12.84 | 12.84 | 5.28 | 1.73 | -3.99 | - |
Provision & Write-off of Bad Debts | 4.35 | 4.35 | 0.32 | 5.06 | 3.99 | 0.96 |
Other Operating Activities | -39.06 | 20.72 | 29.92 | -8.24 | 20.6 | 34.19 |
Change in Accounts Receivable | -1.02 | -1.02 | -57.38 | -125.21 | -75.05 | -75.34 |
Change in Inventory | -14.94 | -14.94 | -5.72 | -59.3 | 3.56 | 22.89 |
Change in Accounts Payable | 43.24 | 43.24 | 17.28 | 6.57 | 82.14 | 8.93 |
Change in Other Net Operating Assets | -12.28 | -12.28 | -7.54 | -18.24 | 68.33 | 21.37 |
Operating Cash Flow | 491.66 | 570.18 | 566.97 | 386.08 | 444.86 | 341.38 |
Operating Cash Flow Growth | -30.04% | 0.57% | 46.85% | -13.21% | 30.31% | 6.82% |
Capital Expenditures | -452.82 | -441.26 | -412.13 | -451.7 | -293.69 | -524.68 |
Sale of Property, Plant & Equipment | 6.79 | 6.79 | 4.92 | 2.74 | - | 0.45 |
Cash Acquisitions | - | - | - | -707.54 | -21.63 | - |
Investment in Securities | -85.15 | -9.06 | 101 | -103.17 | 680 | -238 |
Other Investing Activities | 90.12 | 1.51 | -21.77 | 101.82 | -80.77 | 26.75 |
Investing Cash Flow | -441.05 | -442.01 | -327.98 | -1,158 | 283.91 | -735.48 |
Short-Term Debt Issued | - | 3.96 | 10.11 | - | - | 1,016 |
Long-Term Debt Issued | - | 331.08 | 271.47 | 97.22 | 0.03 | - |
Total Debt Issued | 481.58 | 335.03 | 281.59 | 97.22 | 0.03 | 1,016 |
Short-Term Debt Repaid | - | - | - | - | - | -31.95 |
Long-Term Debt Repaid | - | -333.3 | -186.11 | -17.42 | -9.42 | -6.16 |
Total Debt Repaid | -332.61 | -333.3 | -186.11 | -17.42 | -9.42 | -38.11 |
Net Debt Issued (Repaid) | 148.97 | 1.73 | 95.48 | 79.8 | -9.38 | 978.06 |
Issuance of Common Stock | 10.47 | 21.66 | 3.1 | 13.54 | 6.6 | 3.35 |
Repurchase of Common Stock | -5.65 | -5.65 | -9.8 | -31 | - | - |
Common Dividends Paid | -182.11 | -183.03 | -219.63 | -83.83 | -76.09 | -72.53 |
Other Financing Activities | 14.73 | -2.52 | - | -69.66 | 0.97 | -2.76 |
Financing Cash Flow | -13.6 | -167.82 | -130.84 | -91.15 | -77.9 | 906.11 |
Foreign Exchange Rate Adjustments | -11.99 | 0.44 | 2.5 | -4.59 | 29.86 | -11.27 |
Net Cash Flow | 25.02 | -39.21 | 110.64 | -867.52 | 680.72 | 500.74 |
Free Cash Flow | 38.84 | 128.92 | 154.84 | -65.62 | 151.17 | -183.31 |
Free Cash Flow Growth | -87.43% | -16.74% | - | - | - | - |
Free Cash Flow Margin | 0.90% | 3.02% | 3.68% | -1.83% | 6.03% | -7.74% |
Free Cash Flow Per Share | 0.13 | 0.42 | 0.51 | -0.21 | 0.49 | -0.57 |
Cash Income Tax Paid | 127.88 | 142.75 | 67.11 | 88.45 | 9.16 | 85.05 |
Levered Free Cash Flow | -7.67 | 110.3 | 16.37 | -211.19 | 24.38 | -289.58 |
Unlevered Free Cash Flow | 53.28 | 174.51 | 75.77 | -162.14 | 51.11 | -280.87 |
Change in Working Capital | -69.75 | -69.75 | -115.17 | -209.52 | 91.83 | -7.36 |